• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Anika Therapeutics Inc. - Common Stock (NQ:ANIK)

    9.880 UNCHANGED
    Streaming Delayed Price Updated: 1:00 PM EST, Nov 28, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 9.880
    Bid (Size) 8.750 (100)
    Ask (Size) 14.00 (800)
    Prev. Close 9.880
    Today's Range 9.880 - 9.880
    52wk Range 7.870 - 18.37
    Shares Outstanding 14,828,456
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Anika (ANIK) Q3 2025 Earnings Call Transcript ↗
    Anika (ANIK) Q3 2025 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Anika Therapeutics Inc (NASDAQ:ANIK) Reports Q3 2025 Earnings Beat and Positive Regulatory Milestone ↗
    Anika Therapeutics (ANIK) beat Q3 2025 earnings estimates with a profit of $0.04 per share, driving its stock up over 10% despite a slight revenue miss. 
    Via Chartmill
    Topics Earnings

    Performance

    YTD
    -39.0%
    -39.0%
    1 Month
    +1.3%
    +1.3%
    3 Month
    +8.0%
    +8.0%
    6 Month
    -13.7%
    -13.7%
    1 Year
    -43.7%
    -43.7%

    More News

    Read More
    News headline image
    Anika Therapeutics Reports Filing of Final PMA Module for Hyalofast® Cartilage Repair Scaffold and Data from U.S. Pivotal FastTRACK Phase III Study
    From Anika Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For November 5, 2025 ↗
    Via Benzinga
    News headline image
    Anika to Issue Third Quarter 2025 Financial Results on Wednesday, November 5, 2025
    From Anika Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    ANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Reminds Anika Therapeutics Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Anika Stockholders
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    ANIKA (ANIK) ALERT: Bragar Eagel & Squire, P.C. is Investigating Anika Therapeutics, Inc. on Behalf of Anika Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Anika Therapeutics, Inc. – ANIK
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Anika Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    ANIKA ALERT: Bragar Eagel & Squire, P.C. is Investigating Anika Therapeutics, Inc. on Behalf of Anika Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Bragar Eagel & Squire, P.C. Is Investigating Nutex, Anika, Fluor, and Inspire Medical and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    ANIKA (ANIK) ALERT: Bragar Eagel & Squire, P.C. Continues Investigating Anika Therapeutics, Inc. on Behalf of Anika Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Anika Therapeutics, Inc. - ANIK
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    ANIKA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Anika Therapeutics, Inc. on Behalf of Anika Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    Kirby McInerney LLP Announces Investigation Against Anika Therapeutics, Inc. (ANIK) on Behalf of Investors
    From Kirby McInerney LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK
    From Pomerantz LLP
    Via GlobeNewswire

    Frequently Asked Questions

    Is Anika Therapeutics Inc. - Common Stock publicly traded?
    Yes, Anika Therapeutics Inc. - Common Stock is publicly traded.
    What exchange does Anika Therapeutics Inc. - Common Stock trade on?
    Anika Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Anika Therapeutics Inc. - Common Stock?
    The ticker symbol for Anika Therapeutics Inc. - Common Stock is ANIK on the Nasdaq Stock Market
    What is the current price of Anika Therapeutics Inc. - Common Stock?
    The current price of Anika Therapeutics Inc. - Common Stock is 9.880
    When was Anika Therapeutics Inc. - Common Stock last traded?
    The last trade of Anika Therapeutics Inc. - Common Stock was at 11/28/25 01:00 PM ET
    What is the market capitalization of Anika Therapeutics Inc. - Common Stock?
    The market capitalization of Anika Therapeutics Inc. - Common Stock is 146.51M
    How many shares of Anika Therapeutics Inc. - Common Stock are outstanding?
    Anika Therapeutics Inc. - Common Stock has 147M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.